Haleon plc (LSE/NYSE: HLN), the consumer health company behind brands including Sensodyne, Panadol and Centrum, has announced the purchase of 12,572,956 ordinary shares between 2 and 6 November 2026 under its share buyback programme, which was originally announced on 29 October 2026. All shares acquired will be held as treasury shares. The disclosure, made on 9 November 2026, also confirms the updated voting rights figure that shareholders must use to assess notification obligations under the FCA's Disclosure Guidance and Transparency Rules.

Key Points

  • Haleon plc (HLN) — dual-listed on the London Stock Exchange and NYSE
  • 12,572,956 ordinary shares of £0.01 each purchased across five trading days and designated as treasury shares
  • Volume weighted average prices ranged from 320.44p on 2 November to 340.46p on 5 November 2026
  • Investors should watch for further weekly buyback disclosures as the programme continues

Five-Day Buyback Activity: Share Volumes and Prices Between 2–6 November 2026

Haleon purchased shares across all five trading days in the period. On 2 November, 2,612,966 shares were acquired at a volume weighted average price (VWAP) of 320.44p, with prices ranging from 316.20p to 323.20p. On 3 November, 2,649,689 shares were bought at a VWAP of 327.46p. Activity on 4 November covered 2,010,923 shares at a VWAP of 331.15p, while 5 November saw 2,318,478 shares acquired at a VWAP of 340.46p — the highest average for the week. On 6 November, 2,980,900 shares were purchased at a VWAP of 333.28p. All transactions were executed on the London Stock Exchange.

Treasury Share Holdings and Updated Voting Rights Following Settlement

Following settlement of these transactions, Haleon's registered share capital stands at 8,808,341,409 ordinary shares of £0.01 each. Of these, 28,809,916 are now held as treasury shares and carry no voting rights. The announcement confirms that the number of ordinary shares with active voting rights is 8,779,531,493. This figure is the reference shareholders must use when calculating whether they are required to disclose an interest, or a change in interest, in Haleon under applicable FCA transparency rules. A full breakdown of individual trades is available via the London Stock Exchange RNS system.

Haleon's Consumer Health Portfolio and Its Relevance to Capital Returns

Haleon operates exclusively in consumer health, spanning six product categories: Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its brand portfolio includes Advil, Centrum, Panadol, Sensodyne, Voltaren, Theraflu, and others trusted by more than one billion consumers globally. The buyback programme reflects ongoing capital allocation decisions by a company focused entirely on consumer health. Investors may be watching the pace and pricing of further repurchases as an indicator of management's confidence in the balance sheet and the valuation of the business at current levels.